Skip to main content

Twin Cities med-tech company NxThera to be sold to Boston Scientific in $400M deal

NxThera also will spin out a yet-to-be-named startup that will target the prostate cancer market.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.